JQ1 (+/-)
-
- Applikation
- Inhibition (Inh)
- Verwendungszweck
- Bromodomain inhibitor
- Produktmerkmale
- JQ1 is a potent BET bromodomain inhibitor. IC50 = 17.7, 32.6, 76.9 and 12942 nM respectively for BRD2 (N-terminal (N)), BRD4 (C-terminal (C)), BRD4 (N) and CREBBP respectively. Competitive binding by JQ1 displaces the BRD4 fusion oncoprotein from chromatin, prompting squamous differentiation and specific antiproliferative effects in BRD4-dependent cell lines and patient-derived xenograft models establishing proof-of-concept for targeting protein-protein interactions of epigenetic readers.
- Reinheit
- >98 %
- Chemical Name
- (6R,S)-4-(4-Chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetic acid 1,1-dimethylethyl ester
- Formel
- C23H25ClN4O2S
- Löslichkeit
- Soluble in DMSO (up to 9 mg/ml) or in Ethanol (up to 9 mg/ml) with warming.
-
-
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Powder
- Vorsichtsmaßnahmen
-
GHS – Classification
Pharmacologically active compound that has not been fully tested
May be harmful if swallowed, inhaled or absorbed through skin
Exposure may cause irritation to skin, eyes and upper respiratory tract
Specific target organ toxicity - unknown - Lagerung
- RT
-
- Hintergrund
- Epigenetics,Proliferation,Bromodomain,Cancer,Posttranslational modification,Chromatin
- Molekulargewicht
- 457.00
- CAS-Nummer
- 1268524-69-1
-